Reduction of iron neurotoxicity in intracerebral haemorrhage

Affiliations

¹ The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia; The George Institute for Global Health China at Peking University Health Sciences Center, Beijing, China. Electronic address: canderson@georgeinstitute.org.au.

Comment

Craig S Anderson. Lancet Neurol. 2019 May.

. 2019 May;18(5):416-417.

doi: 10.1016/S1474-4422(19)30108-5. Epub 2019 Mar 18.

¹ The George Institute for Global Health, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia; The George Institute for Global Health China at Peking University Health Sciences Center, Beijing, China. Electronic address: canderson@georgeinstitute.org.au.

No abstract available

Comment on

Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial.
Selim M, Foster LD, Moy CS, Xi G, Hill MD, Morgenstern LB, Greenberg SM, James ML, Singh V, Clark WM, Norton C, Palesch YY, Yeatts SD; i-DEF Investigators. Selim M, et al. Lancet Neurol. 2019 May;18(5):428-438. doi: 10.1016/S1474-4422(19)30069-9. Epub 2019 Mar 18. Lancet Neurol. 2019. PMID: 30898550 Free PMC article. Clinical Trial.